Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Fetal Aortic Valvuloplasty Procedure, Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter, Trek RX and Mini Trek RX Coronary Dilatation Catheter.
- Who it may be relevant to
- Registry conditions: Hypoplastic Left Heart Syndrome. Basic parameters: up to 45 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of Outcomes of Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome
Overview
The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS).
Detailed description
The condition occurs when part of the heart doesn't develop properly so the heart is not able to pump blood around the body effectively. Babies born with this condition require surgery and are often left with a lifelong heart disability. A number of babies with this condition will die during pregnancy or within the first year of life (approximately 10-40%). We are investigating a treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve. The aortic valve function is to allow easy flow from the heart to the body and prevent blood from returning to the heart (regurgitation). This is called fetal aortic valvuloplasty. A number of studies have shown promising results, including a higher of the baby surviving with both sides of the heart functioning (as opposed to only the right side), this may also lead to longer survival with a better quality of life. However, we do not have enough information to say this is always the best way to manage the condition. Currently, parents of babies with this condition, who meet certain eligibility criteria, are offered fetal aortic valvuloplasty during pregnancy. The alternative option is not to intervene during pregnancy but instead monitor the baby with regular ultrasounds. We call this conservative management.
Interventions
- Procedure Fetal Aortic Valvuloplasty Procedure
Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro. - Device Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter
Balloon Catheter - Device Trek RX and Mini Trek RX Coronary Dilatation Catheter
Coronary Dilation Catheter
Primary outcome measures
- Number of cases in which the procedure was successful [Time frame: Baseline]
- Number of cases in which a biventricular repair was achieved [Time frame: Baseline]
- Number cases with pulmonary hypertension [Time frame: Baseline]
Secondary outcome measures (3)
- Number of cases delivered prematurely [Time frame: Baseline]
- Number of cases with perinatal death [Time frame: Baseline]
- Number of maternal complications [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Pregnant women 18-45 years of age.
- Gestational age between 21 0/7 and 29 6/7 weeks of gestation
- The mother must be healthy enough to undergo surgery.
- The individual being enrolled must be able to provide informed consent.
- Dominant cardiac defect is valvar
- Evolving hypoplastic left heart syndrome defined as depressed left ventricle systolic and at least one of the following:
- Retrograde flow in the transverse aortic arch
- Two of the following: (1) left to right flow across the atrial septum (bulging of the septum left to right in cases of intact atrial septum); (2) monophasic mitral valve inflow; (3) bidirectional flow in the pulmonary veins.
- Potential for a technically successful and postnatal biventricular outcome defined as left ventricle long axis Z-score equal or greater than -2 PLUS at least 4 of the following 5 criteria:
- Left ventricle long axis Z-score more than zero
- Left ventricle short axis Z-score more than zero
- Aortic annulus Z-score more than -3.5
- Mitral valve annulus Z-score more than -2
- Left ventricle generating a maximal instantaneous gradient (MIG) equal or greater than 20 mmHg (or by mitral regurgitation jet greater than or equal to 20 mmHg).
Exclusion criteria
- Patient is less than 18 years of age or more than 45 years of age.
- Contraindication to anesthesia or surgery
- Preterm labor or cervical length <20 mm at enrollment or uterine anomaly strongly predisposing to preterm delivery.
- Other fetal anomalies that significantly impact fetal/neonatal survival (e.g., congenital diaphragmatic hernia, bilateral renal agenesis, etc.)
- Fetal aneuploidy and pathogenic findings on Karyotype or Microarray that impact significantly the fetal/neonatal survival.
- Cases with all the following criteria:
- Left ventricle pressure ≤ 47 mmHg
- MV dimension Z-score < 0.1
- MV inflow time Z-score < -2
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Mayo Clinic in Rochester — Rochester
Identifiers
NCT: NCT06342999 · 22-012399